Review Article
Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis
Table 2
Summary of included studies.
| | Included trials | Subject | Age | Type of cancer pain | Intervention | Outcomes | | (experimental/control) | (years; experimental/control) | Experimental | Control |
| | CL2014 | 42/38 | Unclear | Liver cancer | CKI + TACE | TACE | Total pain relief rate |
| | DL2008 | 20/20 | 51 (28–65)/53 (26–66) | Liver cancer | CKI + TACE | TACE | Total pain relief rate; quality of life; adverse events |
| | DL2010 | 30/30 | 51 (37–66)/50 (36–66) | Liver cancer | CKI + TACE | TACE | Total pain relief rate; quality of life |
| | FLW2011 | 40/40 | 66/65 | Gastric cancer | CKI + FOLFOX | FOLFOX | Total pain relief rate; adverse events |
| | GJL2007 | 32/31 | 60 (43,71) | Lung cancer | CKI + NP | NP | Total pain relief rate; quality of life; adverse events |
| | LYH2011 | 83/83 | 71.4 (60–83)/72.7 (61–85) | Gastric cancer | CKI + FOLFOX | FOLFOX | Total pain relief rate |
| | LYR2013 | 44/44 | 52.8 ± 14.5 | Lung cancer | CKI + GC | GC | Total pain relief rate; adverse events |
| | SJ2012 | 18/14 | 62.65 (33,81) | Lung cancer | CKI + NP | NP | Total pain relief rate; quality of life |
| | SXW2012 | 54/52 | 52.5 (32–73)/53.1 (31–72) | Lung cancer | CKI + NP | NP | Total pain relief rate; quality of life; adverse events |
| | WHJ2006 | 44/43 | 54 (33,76) | Lung cancer | CKI + NP | NP | Total pain relief rate; quality of life; adverse events |
| | WS2014 | 107/104 | 55.6/54.5 | Liver cancer | CKI + TACE | TACE | Total pain relief rate; quality of life; adverse events |
| | XJX2013 | 60/60 | 18–75 | Gastric cancer | CKI + FOLFOX | FOLFOX | Total pain relief rate |
| | XXD2006 | 45/44 | 54 (32,71) | Colorectal cancer | CKI + FOLFOX | FOLFOX | Total pain relief rate; quality of life |
| | YJ2007 | 64/62 | 56 (30–78)/60 (33–75) | Colorectal cancer | CKI + FOLFOX | FOLFOX | Total pain relief rate; quality of life |
| | YZG2012 | 50/40 | 56 (40,78)/58 (43,76) | Lung cancer | CKI + GC | GC | Total pain relief rate; quality of life; adverse events |
| | ZJC2012 | 33/33 | 52.3 ± 6.7 | Colorectal cancer | CKI + FOLFOX | FOLFOX | Total pain relief rate; quality of life |
|
|
CKI: compound kushen injection; TACE: Transhepatic Arterial Chemotherapy and Embolization; FOLFOX: oxaliplatin + calcium folinate + fluorouracil; NP: Navelbine + cisplatin; GC: gemcitabine + carboplatin.
|
